Innovative, Collaborative Care for Preserving Fertility
Cleveland Clinic physicians collaborating across disciplines are combining innovative interventions with well-established methods to preserve fertility for patients receiving gonadotoxic treatment for...
View ArticleClik here to view.
Photo Essay: Support Services at Cleveland Clinic
Thanks to generous donor support, Cleveland Clinic Cancer Institute is able to offer support services to help patients and their care partners throughout their cancer journey. The Taussig Cancer...
View ArticleUpdate on Phase 1 Trial of Preventive Breast Cancer Vaccine
Current results from the phase 1 clinical trial of a novel vaccine under investigation at Cleveland Clinic were presented at the San Antonio Breast Cancer Symposium on December 6, 2023. The trial was...
View ArticleAdvanced Practice Provider-Led Virtual Anemia Clinic Improves Patient Access
An increasing volume of classical hematology referrals, coupled with provider shortages, poses a number of challenges, especially as it relates to access to care. To address this gap, Cleveland Clinic...
View ArticleTrial for Patients 75 and Older with Diffuse Large B-Cell Lymphoma Helps...
Diffuse large B-cell lymphoma (DLBCL) is curable in roughly 60% of cases, yet an estimated 10-15% of patients 80+ years old with the disease receive no treatment, due to concerns about tolerance to...
View ArticleMajor Study Identifies Global Disparities in Drug Toxicity for Multiple...
There are distinct differences in adverse events patients around the world experience during multiple myeloma treatment, according to data presented at the 2023 American Society of Clinical Oncology...
View ArticleThe Evolution of Gamma Knife Technology (Podcast)
Since the inception of Gamma Knife® technology more than 55 years ago, this stereotactic radiosurgery platform designed to treat brain tumors has never stopped evolving. “In its current iteration,...
View ArticleGene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia
Results from the phase 1/2 RUBY and EdiThal trials suggest that CRISPR/CASP 12 gene editing has the potential to cure sickle cell disease and transfusion-dependent beta-thalassemia (TDT). The...
View ArticlePossibilities of CRISPR Technology (Podcast)
The gene editing technology CRISPR offers potential for treating both hematologic cancer and solid tumors. “The promise with the technology is now we can use our own immune system and use it as a...
View ArticleHaploidentical Bone Marrow Transplant Has Durable Engraftment in Patients...
Reduced-intensity haploidentical bone marrow transplantation (BMT) for sickle cell disease has resulted in durable engraftment with low mortality, according to the Blood and Marrow Transplant Clinical...
View Article
